Transforming Growth Factor-β, Bioenergetics, and Mitochondria in Renal Disease

Seminars in Nephrology

Volumn 32, Issue 3, 2012, Pages 295-303

  Casalena, Gabriella ^a   Daehn, Ilse ^a   Bottinger, Erwin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cytokine; Fibrosis; Mitochondria; Signal transduction

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN; CYTOKINE; TRANSFORMING GROWTH FACTOR BETA;

AGING; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; BIOENERGY; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; DEGENERATIVE DISEASE; DEVELOPMENTAL DISORDER; EMBRYO DEVELOPMENT; ENERGY METABOLISM; FIBROSIS; GENETIC CONSERVATION; HOMEOSTASIS; HUMAN; INVERTEBRATE; KIDNEY DISEASE; METABOLISM; MITOCHONDRION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE REPAIR; VERTEBRATE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; DNA, MITOCHONDRIAL; ENERGY METABOLISM; FIBROSIS; HUMANS; KIDNEY; MICE; MITOCHONDRIA; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; SIRTUIN 1; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84864150374     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.04.009     Document Type: Article

References (93)

1. Xue J.L., Ma J.Z., Louis T.A., Collins A.J. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001, 12:2753-2758.
2. Collins A.J., Foley R.N., Herzog C., et al. Excerpts from the US Renal Data System 2009 annual data report. Am J Kidney Dis 2010, 55(Suppl 1):S1-S420. A6-7.
3. Bottinger E.P. TGF-beta in renal injury and disease 4. Semin Nephrol 2007, 27:309-320.
4. Kagami S., Border W.A., Miller D.E., Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-2437.
5. Okuda S., Languino L.R., Ruoslahti E., Border W.A. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix [erratum: J Clin Invest. 1990;86:2175]. J Clin Invest 1990, 86:453-462.
6. Sharma K., Ziyadeh F.N. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994, 267:F1094-F1101.
7. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
8. Ziyadeh F.N. Mediators of diabetic renal disease: the case for tgf-beta as the major mediator. J Am Soc Nephrol 2004, 15(Suppl 1):S55-S57.
9. Cortes P., Riser B., Narins R.G. Glomerular hypertension and progressive renal disease: the interplay of mesangial cell stretch, cytokine formation and extracellular matrix synthesis. Contrib Nephrol 1996, 118:229-233.
10. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
11. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
12. Xavier S., Niranjan T., Krick S., et al. TbetaRI independently activates Smad- and CD2AP-dependent pathways in podocytes. J Am Soc Nephrol 2009, 20:2127-2137.
13. ten Dijke P., Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004, 29:265-273.
14. Davis B.N., Hilyard A.C., Lagna G., Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008, 454:56-61.
15. Pang L., Qiu T., Cao X., Wan M. Apoptotic role of TGF-beta mediated by Smad4 mitochondria translocation and cytochrome c oxidase subunit II interaction. Exp Cell Res 2011, 317:1608-1620.
16. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112:1486-1494.
17. Terada Y., Hanada S., Nakao A., Kuwahara M., Sasaki S., Marumo F. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney 7. Kidney Int 2002, 61:94-98.
18. Fujimoto M., Maezawa Y., Yokote K., et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy 11. Biochem Biophys Res Commun 2003, 305:1002-1007.
19. Hou C.C., Wang W., Huang X.R., et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-{beta} signaling and fibrosis in rat remnant kidney. Am J Pathol 2005, 166:761-771.
20. Schiffer M., Bitzer M., Roberts I.S., et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108:807-816.
21. Savill J., Mooney A., Hughes J. What role does apoptosis play in progression of renal disease?. Curr Opin Nephrol Hypertens 1996, 5:369-374.
22. Kumar D., Zimpelmann J., Robertson S., Burns K.D. Tubular and interstitial cell apoptosis in the streptozotocin-diabetic rat kidney. Nephron Exp Nephrol 2004, 96:E77-E88.
23. Susztak K., Ciccone E., McCue P., Sharma K., Bottinger E.P. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoSMed 2005, 2:e45.
24. Schiffer M., Mundel P., Shaw A.S., Bottinger E.P. A novel role for the adaptor molecule CD2-associated protein in TGF-beta-induced apoptosis. J Biol Chem 2004, 279:37004-37012.
25. Mundel P., Shankland S.J. Podocyte biology and response to injury. J Am Soc Nephrol 2002, 13:3005-3015.
26. Lin J.D. Minireview: the PGC-1 coactivator networks: chromatin-remodeling and mitochondrial energy metabolism. Mol Endocrinol 2009, 23:2-10.
27. Canto C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009, 20:98-105.
28. Otera H., Mihara K. Molecular mechanisms and physiologic functions of mitochondrial dynamics. J Biochem 2011, 149:241-251.
29. Verhoeven K., Claeys K.G., Zuchner S., et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 2006, 129:2093-2102.
30. Olichon A., Landes T., Arnaune-Pelloquin L., et al. Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis. J Cell Physiol 2007, 211:423-430.
31. Brooks C., Wei Q., Cho S.G., Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 2009, 119:1275-1285.
32. Krick S., Shi S., Ju W., et al. Mpv17l protects against mitochondrial oxidative stress and apoptosis by activation of Omi/HtrA2 protease. Proc Natl Acad Sci U S A 2008, 105:14106-14111.
33. Wang W., Wang Y., Long J., et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab 2012 Feb 8, 15(2):186-200.
34. Yoon Y.S., Lee J.H., Hwang S.C., Choi K.S., Yoon G. TGF beta1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells. Oncogene 2005, 24:1895-1903.
35. Brooks C., Cho S.G., Wang C.Y., Yang T., Dong Z. Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis. Am J Physiol Cell Physiol 2011, 300:C447-C455.
36. Zamani N., Brown C.W. Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure. Endocr Rev 2011, 32:387-403.
37. Yadav H., Quijano C., Kamaraju A.K., et al. Protection from obesity and diabetes by blockade of TGF-beta/Smad3 signaling. Cell Metab 2011, 14:67-79.
38. Michaeloudes C., Sukkar M.B., Khorasani N.M., Bhavsar P.K., Chung K.F. TGF-beta regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2011, 300:L295-L304.
39. Sayeed A., Meng Z., Luciani G., Chen L.C., Bennington J.L., Dairkee S.H. Negative regulation of UCP2 by TGFbeta signaling characterizes low and intermediate-grade primary breast cancer. Cell Death Dis 2010, 1:e53.
40. Pacher P., Sharma K., Csordas G., Zhu Y., Hajnoczky G. Uncoupling of ER-mitochondrial calcium communication by transforming growth factor-beta. Am J Physiol Renal Physiol 2008, 295:F1303-F1312.
41. Mishra R., Cool B.L., Laderoute K.R., Foretz M., Viollet B., Simonson M.S. AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem 2008, 283:10461-10469.
42. Frye R.E., Rossignol D.A. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 2011, 69:41R-47R.
43. Calvo S., Jain M., Xie X., et al. Systematic identification of human mitochondrial disease genes through integrative genomics. Nat Genet 2006, 38:576-582.
44. Hao C.M., Haase V.H. Sirtuins and their relevance to the kidney. J Am Soc Nephrol 2010, 21:1620-1627.
45. Brunet A., Sweeney L.B., Sturgill J.F., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
46. Verdin E., Hirschey M.D., Finley L.W., Haigis M.C. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 2010, 35:669-675.
47. Kume S., Haneda M., Kanasaki K., et al. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 2007, 282:151-158.
48. Li J., Qu X., Ricardo S.D., Bertram J.F., Nikolic-Paterson D.J. Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol 2010, 177:1065-1071.
49. Li C., Cai F., Yang Y., et al. Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: involvement of SIRT1 and TGF-beta1 pathway. Eur J Pharmacol 2010, 649:382-389.
50. Minagawa S., Araya J., Numata T., et al. Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-beta-induced senescence of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2011, 300:L391-L401.
51. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem J 2009, 417:1-13.
52. Andreyev A.Y., Kushnareva Y.E., Starkov A.A. Mitochondrial metabolism of reactive oxygen species. Biochemistry 2005, 70:200-214.
53. Kwong J.Q., Beal M.F., Manfredi G. The role of mitochondria in inherited neurodegenerative diseases. J Neurochem 2006, 97:1659-1675.
54. Sugamura K., Keaney J.F. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 2011, 51:978-992.
55. Perico N., Remuzzi G., Benigni A. Aging and the kidney. Curr Opin Nephrol Hypertens 2011, 20:312-317.
56. Singh D.K., Winocour P., Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 2011, 7:176-184.
57. Ribeiro A., Bronk S.F., Roberts P.J., Urrutia R., Gores G.J. The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology 1999, 30:1490-1497.
58. Herrera B., Alvarez A.M., Sanchez A., et al. Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor (beta) in fetal hepatocytes. FASEB J 2001, 15:741-751.
59. Herrera B., Fernandez M., Alvarez A.M., et al. Activation of caspases occurs downstream from radical oxygen species production, Bcl-xL down-regulation, and early cytochrome C release in apoptosis induced by transforming growth factor beta in rat fetal hepatocytes. Hepatology 2001, 34:548-556.
60. Carmona-Cuenca I., Roncero C., Sancho P., et al. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J Hepatol 2008, 49:965-976.
61. Cucoranu I., Clempus R., Dikalova A., et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005, 97:900-907.
62. Graham D., Huynh N.N., Hamilton C.A., et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009, 54:322-328.
63. Chacko B.K., Reily C., Srivastava A., et al. Prevention of diabetic nephropathy in Ins2(+/)(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem J 2010, 432:9-19.
64. Mizuguchi Y., Chen J., Seshan S.V., Poppas D.P., Szeto H.H., Felsen D. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am J Physiol Renal Physiol 2008, 295:F1545-F1553.
65. Doleris L.M., Hill G.S., Chedin P., et al. Focal segmental glomerulosclerosis associated with mitochondrial cytopathy. Kidney Int 2000, 58:1851-1858.
66. Hotta O., Inoue C.N., Miyabayashi S., Furuta T., Takeuchi A., Taguma Y. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int 2001, 59:1236-1243.
67. Inoue K., Nakada K., Ogura A., et al. Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. Nat Genet 2000, 26:176-181.
68. Hagiwara M., Yamagata K., Capaldi R.A., Koyama A. Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis. Kidney Int 2006, 69:1146-1152.
69. Papeta N., Zheng Z., Schon E.A., et al. Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice. J Clin Invest 2010, 120:4055-4064.
70. Wang Y., Wang Y.P., Tay Y.C., Harris D.C. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000, 58:1797-1804.
71. Spinazzola A., Viscomi C., Fernandez-Vizarra E., et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 2006, 38:570-575.
72. Weiher H., Noda T., Gray D.A., Sharpe A.H., Jaenisch R. Transgenic mouse model of kidney disease: insertional inactivation of ubiquitously expressed gene leads to nephrotic syndrome. Cell 1990, 62:425-434.
73. Binder C.J., Weiher H., Exner M., Kerjaschki D. Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: a model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol 1999, 154:1067-1075.
74. Heine U.I., Burmester J.K., Flanders K.C., et al. Localization of transforming growth factor-α1 in mitochondria of murine heart and liver. Cell Regul 1991, 2:467-477.
75. Jullig M., Stott N.S. Mitochondrial localization of Smad5 in a human chondrogenic cell line. Biochem Biophys Res Commun 2003, 307:108-113.
76. Sun Y., Zhou J., Liao X., et al. Disruption of Smad5 gene induces mitochondria-dependent apoptosis in cardiomyocytes. Exp Cell Res 2005, 306:85-93.
77. John B., Enright A.J., Aravin A., Tuschl T., Sander C., Marks D.S. Human MicroRNA targets. PLoS Biol 2004, 2:e363.
78. Jiang Q., Wang Y., Hao Y., et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009, 37:D98-D104.
79. Kato M., Arce L., Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol 2009, 4:1255-1266.
80. Harvey S.J., Jarad G., Cunningham J., et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 2008, 19:2150-2158.
81. Ho J., Ng K.H., Rosen S., Dostal A., Gregory R.I., Kreidberg J.A. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 2008, 19:2069-2075.
82. Shi S., Yu L., Chiu C., et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol 2008, 19:2159-2169.
83. Li J., Donath S., Li Y., Qin D., Prabhakar B.S., Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet 2010, 6:e1000795.
84. Minones-Moyano E., Porta S., Escaramis G., et al. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 2011, 20:3067-3078.
85. Chen H.C., Chen G.H., Chen Y.H., et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009, 100:1002-1011.
86. Chan S.Y., Zhang Y.Y., Hemann C., Mahoney C.E., Zweier J.L., Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009, 10:273-284.
87. Chen Z., Li Y., Zhang H., Huang P., Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010, 29:4362-4368.
88. Mizuno Y., Tokuzawa Y., Ninomiya Y., et al. miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. FEBS Lett 2009, 583:2263-2268.
89. Rane S., He M., Sayed D., et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009, 104:879-886.
90. *. Annu Rev Genet 2009, 43:95-118.
91. Lin P.H., Pan Z., Zheng L., Li N., Danielpour D., Ma J.J. Overexpression of Bax sensitizes prostate cancer cells to TGF-beta induced apoptosis. Cell Res 2005, 15:160-166.
92. Chipuk J.E., Bhat M., Hsing A.Y., Ma J., Danielpour D. Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem 2001, 276:26614-26621.
93. Cleland M.M., Norris K.L., Karbowski M., Wang C., Suen D.F., Jiao S., et al. Bcl-2 family interaction with the mitochondrial morphogenesis machinery. Cell Death Differ 2011, 18:235-247.